Treatment Outcome of Adult Burkitt Lymphoma in Japanese Patients with Modified LMB Protocol : A Single Center Retrospective Analysis

この論文にアクセスする

この論文をさがす

著者

    • NISHIKII Hidekazu
    • Department of Hematology, Graduate School of Comprehensive Human Sciences, University of Tsukuba
    • KONDO Yuzuru
    • Department of Pathology, Graduate School of Comprehensive Human Sciences, University of Tsukuba
    • OKOSHI Yasushi
    • Department of Hematology, Graduate School of Comprehensive Human Sciences, University of Tsukuba
    • SUZUKAWA Kazumi
    • Department of Hematology, Graduate School of Comprehensive Human Sciences, University of Tsukuba
    • HASEGAWA Yuichi
    • Department of Hematology, Graduate School of Comprehensive Human Sciences, University of Tsukuba
    • YOKOYAMA Yasuhisa
    • Department of Hematology, Graduate School of Comprehensive Human Sciences, University of Tsukuba
    • ENAMI Terukazu
    • Department of Hematology, Graduate School of Comprehensive Human Sciences, University of Tsukuba
    • NOGUCHI Masayuki
    • Department of Pathology, Graduate School of Comprehensive Human Sciences, University of Tsukuba
    • CHIBA Shigeru
    • Department of Hematology, Graduate School of Comprehensive Human Sciences, University of Tsukuba

抄録

The prognosis of adult Burkitt lymphoma (BL) has improved in western countries since the introduction of high-dose methotrexate (HD-MTX)-containing chemotherapy. Here we analyzed nine consecutive Japanese patients diagnosed with BL at our institution. All except for the three elderly (> 70 years) patients were treated with a regimen including 13 g/m<SUP>2</SUP> HD-MTX in total, divided into 3 cycles. The median follow-up period was 56 months (range 38-118). All the nine patients achieved complete remission and have not shown any disease progression, including the three elderly patients who received reduced doses or alternative treatments. These observations suggest that chemotherapy including 13 g/m<SUP>2</SUP> HD-MTX in total is tolerable and effective in Japanese adult BL patients aged < 70 and that BL is curable even if developed in those who are > 70 years. [<I>J Clin Exp Hematopathol 51(</I><I>2) </I>: <I>109-114, 2011</I>]

収録刊行物

  • Journal of clinical and experimental hematopathology

    Journal of clinical and experimental hematopathology 51(2), 109-114, 2011-11-01

    日本リンパ網内系学会

参考文献:  16件中 1-16件 を表示

各種コード

  • NII論文ID(NAID)
    10030207641
  • NII書誌ID(NCID)
    AA11556796
  • 本文言語コード
    ENG
  • 資料種別
    ART
  • ISSN
    13464280
  • データ提供元
    CJP書誌  J-STAGE 
ページトップへ